Acadia’s 2025 Finish Line: Revenue Milestone, Inflation Rebates, and a Growth Engine Check

What the numbers say, in plain English

Acadia wrapped Q4 2025 with GAAP total revenues of $284 million and pushed full-year GAAP revenues to $1.07 billion, marking 9% year-over-year quarterly growth and 12% for the year. Non-GAAP revenues followed a similar arc: $298 million in the fourth quarter and $1.08 billion for the year, up 16% quarterly and 14% annually. In short, the book closes on a year that feels heavier on volume than on price.

Breaking down the line items that actually moved the needle, net sales from NUPLAZID came in at $174 million on a GAAP basis for Q4, with non-GAAP net sales at $189 million; DAYBUE contributed $110 million in net sales for Q4. The press release highlights momentum in both franchises, with DAYBUE expanding reach in the community and continued support from named patient programs outside the U.S.

For the year, Acadia signals a continued tilt toward growth engines rather than a single blockbuster: the company disclosed a forward-looking revenue forecast for 2026 of $1.22 to $1.28 billion in total revenues, with NUPLAZID net sales pegged at $760 to $790 million and DAYBUE net sales at $460 to $490 million. Those figures imply a continued mix shift toward the two medicines that drive the top line, even as the company chalks up one-time items along the way.

A few more texture points: management notes that the fourth quarter benefited from an IRA-related pricing dynamic, including a non-recurring IRA rebate accrual charge in the estimate, which factored into GAAP net sales. The company also emphasizes ongoing progress in its non-GAAP framework, suggesting investors should focus on the underlying operating trajectory rather than just headline revenue growth.

Products in the foreground: NUPLAZID, DAYBUE, and a powdery expansion plan

NUPLAZID remains the larger revenue contributor, with GAAP net sales of $174 million in Q4 and non-GAAP net sales of $189 million, even as inflation-related invoicing and rebates shape quarterly results. DAYBUE produced $110 million in Q4 net sales, reflecting continued penetration and an expanding footprint outside the U.S. The combination of these two medicines anchors Acadia’s growth story and sets the tone for 2026 guidance.

Beyond the near-term numbers, the company flags a new formulation—DAYBUE STIX powder—as a potential catalyst as it approaches a full launch in early Q2 of this year. The strategic emphasis on formulation innovations alongside geographic expansion signals that Acadia is aiming to lift both volume and patient reach in a year where payer dynamics and access programs will matter as much as the headline revenue line.

Looking ahead: what the 2026 revenue forecast could portend for EPS and margins

Guidance for 2026 envisions total revenues of $1.22 to $1.28 billion, with NUPLAZID and DAYBUE split roughly as you’d expect given their current trajectories. The implied scale-up depends on multiple moving parts: continued volume growth, mature pricing, and the elusive margin story as the company manages manufacturing, distribution, and program costs, including rebates tied to inflation and regulatory incentives.

In terms of earnings per share (EPS), the headline remains revenue-centric, but the bridge to EPS will hinge on gross margins and operating expenses, plus any ongoing adjustments for non-GAAP items. If the mix stays favorable—more net sales from NUPLAZID and DAYBUE with manageable inflation-related charges—investors might see impulse toward a higher EPS trajectory even if the GAAP figure remains complex due to those one-time items.

For analysts and stock-watchers, the “EPS consensus” question will be as important as the revenue forecast itself: will margins widen as the business scales, or will rebate and inflation-related quirks compress profits in the near term? The answer will likely hinge on how much of the 2026 revenue growth translates into operating leverage and how durable the U.S. and international demand proves to be in a year where payer dynamics continue to evolve.

Leadership note: a milestone year and a cautiously optimistic tone

In a candid statement from San Diego, ACAD Chief Executive Officer Catherine Owen Adams framed 2025 as a milestone year—“we surpassed $1 billion in annual revenue for the first time.” The tone blends celebration with a practical eye toward the programmatic roadmap, including the R&D pipeline anchored by remlifanserin and the Phase 2 RADIANT study in Alzheimer's disease psychosis. Top-line results are anticipated between August and October 2026, with the potential to further diversify Acadia’s growth driver beyond NUPLAZID and DAYBUE.

From a strategic standpoint, the release reinforces the notion that Acadia intends to stay the course on its two-drug core, while investing in pipeline progress and new formulations that could extend product life cycles and broaden patient access. It’s a classic move: secure a revenue base and then tilt toward innovation to sustain growth, all while navigating a landscape where inflation rebates and IRA-related mechanics are not just footnotes but active factors in the P&L.

Implications for peers and the sector

Acadia’s narrative is a reminder to investors that the value of a biotech franchise often hinges on a stable, growing core product alongside a credible pipeline story. For sector peers, the 2025 show-and-tell underlines a few themes: durable franchises with payer-friendly access programs can deliver meaningful revenue growth even amid inflation-driven revenue adjusters; a successful launch of a new formulation (DAYBUE STIX) can meaningfully shift a company’s growth profile; and forward-looking guidance—especially around revenue forecasts—will be the primary lexicon by which investors judge late-stage biotech names in 2026.

In short, Acadia’s 2025 results aren’t a one-off victory lap; they are a practical scaffold for discussing EPS trajectory, revenue forecasting, and the durability of two major product lines. For peers, the takeaway is simple: demonstrate that you can convert clinical momentum into steady, scalable commercial growth, and you’ll earn room to weather the inevitable pressurized periods when rebates, inflation, or regulatory invoices bite into the quarterly cadence.

Risks and caveats to keep in mind

Forward-looking numbers are always subject to variation. Actual performance will depend on competitive dynamics, regulatory developments, payer coverage decisions, manufacturing scalability, and the ongoing impact of rebates and inflation-related accounting. The complexity around one-time charges tied to IRA rebates means investors should watch how the company reports these items in future quarters, as well as how gross margins trend as product mix evolves.

Bottom line

Acadia’s 2025 performance signals a successful year for a two-drug model that continues to scale. The 2026 revenue forecast sets a clear target, and the company’s push into DAYBUE STIX and ongoing R&D indicates a willingness to expand beyond a couple of core products. For investors, the key questions are simple in form but complex in consequence: will the revenue growth translate into meaningful EPS expansion, and will the 2026 revenue forecast prove durable in a shifting payer landscape?

Watch for the next quarterly cadence where the company will illuminate how the IRA-related dynamics, non-GAAP adjustments, and the cost of launching a new formulation interact with the ongoing trajectory of NUPLAZID and DAYBUE. The path from $1.07 billion to something decisively higher in EPS depends on a few careful steps—steps that Acadia seems ready to take, with a steady hand and a calculator in one pocket and a pipeline prospectus in the other.